Literature DB >> 20369080

Metronomic chemotherapy: Back to the future!

Nicolas André1, Laetitia Padovani, Arnauld Verschuur.   

Abstract

Angiogenesis is crucial for the growth of cancer. As such, it has become an established target to fight cancer. Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration, at close regular intervals, with no prolonged drug-free breaks-is a potential approach to control advanced cancer disease. It is thought to work primarily through antiangiogenic mechanisms and has the property to kill resistant cancer cells and/or to inhibit tumor growth while significantly reducing undesirable toxic side effects. Here, we will discuss potential mechanisms of action of metronomic chemotherapy and briefly review the data regarding the clinical experience with this kind of anticancer treatment. Based on recent insights in the various mechanisms of action, we will try to predict the potential new developments of metronomic chemotherapy in oncology. Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20369080     DOI: 10.1358/dnp.2010.23.2.1475913

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  7 in total

Review 1.  Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

Authors:  Patrick R Lawler; Jack Lawler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

2.  Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Authors:  Fabien Calcagno; Guillaume Mouillet; Olivier Adotevi; Tristan Maurina; Thierry Nguyen; Philippe Montcuquet; E Curtit; F Kleinclauss; Xavier Pivot; Christophe Borg; Antoine Thiery-Vuillemin
Journal:  Med Oncol       Date:  2016-07-11       Impact factor: 3.064

Review 3.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

4.  Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.

Authors:  Li Jia; David J Waxman
Journal:  Cancer Lett       Date:  2012-12-08       Impact factor: 8.679

5.  Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

Authors:  Teresa Di Desidero; Paola Orlandi; Anna Fioravanti; Chiara Cremolini; Fotios Loupakis; Federica Marmorino; Carlotta Antoniotti; Gianluca Masi; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Alfredo Falcone; Guido Bocci
Journal:  Invest New Drugs       Date:  2018-02-27       Impact factor: 3.850

Review 6.  The Concept of Hormesis in Cancer Therapy - Is Less More?

Authors:  Andy Gaya; Charles A Akle; Satvinder Mudan; John Grange
Journal:  Cureus       Date:  2015-04-02

7.  Neuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group.

Authors:  Fousseyni Traoré; Francis Eshun; Boubacar Togo; Jean Jacques Atteby Yao; Mbuli Robert Lukamba
Journal:  J Glob Oncol       Date:  2016-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.